Chinese- REPORT SUMMARY
- TABLE OF CONTENTS
-
Nuclear Medicine and Radiopharmaceutic market report explains the definition, types, applications, major countries, and major players of the Nuclear Medicine and Radiopharmaceutic market. The report mainly contains different types, applications, and regional historical data from 2017-2021 and forecast data from 2022-2028.
The report contains qualitative and quantitative analysis of the entire industry.
The influence of COVID-19 has been considered in the report. Coronavirus Impact is included in Chapter 2. In addition, Strategic Analytics to Boost Productivity and Profitability is included in Chapter 3.
By Player:
Dongcheng?
China Isotope & Radiation?
Nordion?
SIEMENS?
Bayer?
IBA Group?
GE Healthcare?
Lantheus?
Company?
Eli Lilly?
Bracco Imaging?
Jubilant Pharma?
Mallinckrodt?
Navidea?
Advanced Accelerator Applications?
Triad Isotopes?
By Type:
Diagnostic Radioisotopes?
Therapeutic Radioisotopes
By End-User:
Oncology?
Cardiology?
Others?
By Region:
North America
-
United States
-
Canada
-
Mexico
Europe
-
Germany
-
UK
-
Spain
-
France
-
Italy
-
Denmark
-
Finland
-
Norway
-
Sweden
-
Poland
-
Russia
-
Turkey
Asia-Pacific
-
China
-
Japan
-
India
-
South Korea
-
Pakistan
-
Bangladesh
-
Indonesia
-
Thailand
-
Singapore
-
Malaysia
-
Philippines
-
Vietnam
-
Others
South America
-
Brazil
-
Colombia
-
Chile
-
Argentina
-
Venezuela
-
Peru
-
Puerto Rico
-
Ecuador
-
Others
GCC
-
Bahrain
-
Kuwait
-
Oman
-
Qatar
-
Saudi Arabia
-
United Arab Emirates
Africa
-
Nigeria
-
South Africa
-
Egypt
-
Algeriat
-
Others
Oceania
-
Australia
-
New Zealand
TABLE OF CONTENT
1. Global Nuclear Medicine and Radiopharmaceutic Executive Summary
-
1.1 Introduction
-
1.2 Market Panorama, 2022
2 Coronavirus Impact
-
2.1 Nuclear Medicine and Radiopharmaceutic Outlook to 2028- Original Forecasts
-
2.2 Nuclear Medicine and Radiopharmaceutic Outlook to 2028- COVID-19 Affected Forecasts
-
2.3 Impact on Industry
3 Strategic Analytics to Boost Productivity and Profitability
-
3.1 Potential Market Drivers and Opportunities
-
3.2 New Challenges and Strategies
-
3.3 Short Term and Long Term Nuclear Medicine and Radiopharmaceutic Market Trends
4 Key Inferences
5 Market Overview
-
5.1 Current Market Scenario
-
5.2 Porter's Five Forces Analysis
-
5.2.1 Bargaining Power of Suppliers
-
5.2.2 Bargaining Power of Consumers
-
5.2.3 Threat of New Entrants
-
5.2.4 Threat of Substitute Product and Services
-
5.2.5 Competitive Rivalry within the Industry
6 Global Nuclear Medicine and Radiopharmaceutic Market- Recent Developments
-
6.1 Nuclear Medicine and Radiopharmaceutic Market News and Developments
-
6.2 Nuclear Medicine and Radiopharmaceutic Market Deals Landscape
7 Nuclear Medicine and Radiopharmaceutic Raw Materials and Cost Structure Analysis
-
7.1 Nuclear Medicine and Radiopharmaceutic Key Raw Materials
-
7.2 Nuclear Medicine and Radiopharmaceutic Price Trend of Key Raw Materials
-
7.3 Nuclear Medicine and Radiopharmaceutic Key Suppliers of Raw Materials
-
7.4 Nuclear Medicine and Radiopharmaceutic Market Concentration Rate of Raw Materials
-
7.5 Nuclear Medicine and Radiopharmaceutic Cost Structure Analysis
-
7.5.1 Nuclear Medicine and Radiopharmaceutic Raw Materials Analysis
-
7.5.2 Nuclear Medicine and Radiopharmaceutic Labor Cost Analysis
-
7.5.3 Nuclear Medicine and Radiopharmaceutic Manufacturing Expenses Analysis
8 Global Nuclear Medicine and Radiopharmaceutic Import and Export Analysis (Top 10 Countries)
-
8.1 Global Nuclear Medicine and Radiopharmaceutic Import by Region (Top 10 Countries) (2017-2028)
-
8.2 Global Nuclear Medicine and Radiopharmaceutic Export by Region (Top 10 Countries) (2017-2028)
9 Global Nuclear Medicine and Radiopharmaceutic Market Outlook by Types and Applications to 2022
-
9.1 Global Nuclear Medicine and Radiopharmaceutic Consumption and Growth Rate by Type (2017-2022)
-
9.1.1 Global Diagnostic Radioisotopes? Consumption and Growth Rate (2017-2022)
-
9.1.2 Global Therapeutic Radioisotopes Consumption and Growth Rate (2017-2022)
-
9.2 Global Nuclear Medicine and Radiopharmaceutic Consumption and Growth Rate by Application (2017-2022)
-
9.2.1 Global Oncology? Consumption and Growth Rate (2017-2022)
-
9.2.2 Global Cardiology? Consumption and Growth Rate (2017-2022)
-
9.2.3 Global Others? Consumption and Growth Rate (2017-2022)
10 Region and Country-wise Nuclear Medicine and Radiopharmaceutic Market Analysis and Outlook till 2022
-
10.1 Global Nuclear Medicine and Radiopharmaceutic Consumption (2017-2022)
-
10.2 North America Consumption Analysis
-
10.2.1 United States Nuclear Medicine and Radiopharmaceutic Consumption (2017-2022)
-
10.2.2 Canada Nuclear Medicine and Radiopharmaceutic Consumption (2017-2022)
-
10.2.3 Mexico Nuclear Medicine and Radiopharmaceutic Consumption (2017-2022)
-
10.3 Europe Consumption Analysis
-
10.3.1 Germany Nuclear Medicine and Radiopharmaceutic Consumption (2017-2022)
-
10.3.2 UK Nuclear Medicine and Radiopharmaceutic Consumption (2017-2022)
-
10.3.3 Spain Nuclear Medicine and Radiopharmaceutic Consumption (2017-2022)
-
10.3.4 Belgium Nuclear Medicine and Radiopharmaceutic Consumption (2017-2022)
-
10.3.5 France Nuclear Medicine and Radiopharmaceutic Consumption (2017-2022)
-
10.3.6 Italy Nuclear Medicine and Radiopharmaceutic Consumption (2017-2022)
-
10.3.7 Denmark Nuclear Medicine and Radiopharmaceutic Consumption (2017-2022)
-
10.3.8 Finland Nuclear Medicine and Radiopharmaceutic Consumption (2017-2022)
-
10.3.9 Norway Nuclear Medicine and Radiopharmaceutic Consumption (2017-2022)
-
10.3.10 Sweden Nuclear Medicine and Radiopharmaceutic Consumption (2017-2022)
-
10.3.11 Poland Nuclear Medicine and Radiopharmaceutic Consumption (2017-2022)
-
10.3.12 Russia Nuclear Medicine and Radiopharmaceutic Consumption (2017-2022)
-
10.3.13 Turkey Nuclear Medicine and Radiopharmaceutic Consumption (2017-2022)
-
10.4 APAC Consumption Analysis
-
10.4.1 China Nuclear Medicine and Radiopharmaceutic Consumption (2017-2022)
-
10.4.2 Japan Nuclear Medicine and Radiopharmaceutic Consumption (2017-2022)
-
10.4.3 India Nuclear Medicine and Radiopharmaceutic Consumption (2017-2022)
-
10.4.4 South Korea Nuclear Medicine and Radiopharmaceutic Consumption (2017-2022)
-
10.4.5 Pakistan Nuclear Medicine and Radiopharmaceutic Consumption (2017-2022)
-
10.4.6 Bangladesh Nuclear Medicine and Radiopharmaceutic Consumption (2017-2022)
-
10.4.7 Indonesia Nuclear Medicine and Radiopharmaceutic Consumption (2017-2022)
-
10.4.8 Thailand Nuclear Medicine and Radiopharmaceutic Consumption (2017-2022)
-
10.4.9 Singapore Nuclear Medicine and Radiopharmaceutic Consumption (2017-2022)
-
10.4.10 Malaysia Nuclear Medicine and Radiopharmaceutic Consumption (2017-2022)
-
10.4.11 Philippines Nuclear Medicine and Radiopharmaceutic Consumption (2017-2022)
-
10.4.12 Vietnam Nuclear Medicine and Radiopharmaceutic Consumption (2017-2022)
-
10.5 South America Consumption Analysis
-
10.5.1 Brazil Nuclear Medicine and Radiopharmaceutic Consumption (2017-2022)
-
10.5.2 Colombia Nuclear Medicine and Radiopharmaceutic Consumption (2017-2022)
-
10.5.3 Chile Nuclear Medicine and Radiopharmaceutic Consumption (2017-2022)
-
10.5.4 Argentina Nuclear Medicine and Radiopharmaceutic Consumption (2017-2022)
-
10.5.5 Venezuela Nuclear Medicine and Radiopharmaceutic Consumption (2017-2022)
-
10.5.6 Peru Nuclear Medicine and Radiopharmaceutic Consumption (2017-2022)
-
10.5.7 Puerto Rico Nuclear Medicine and Radiopharmaceutic Consumption (2017-2022)
-
10.5.8 Ecuador Nuclear Medicine and Radiopharmaceutic Consumption (2017-2022)
-
10.6 GCC Consumption Analysis
-
10.6.1 Bahrain Nuclear Medicine and Radiopharmaceutic Consumption (2017-2022)
-
10.6.2 Kuwait Nuclear Medicine and Radiopharmaceutic Consumption (2017-2022)
-
10.6.3 Oman Nuclear Medicine and Radiopharmaceutic Consumption (2017-2022)
-
10.6.4 Qatar Nuclear Medicine and Radiopharmaceutic Consumption (2017-2022)
-
10.6.5 Saudi Arabia Nuclear Medicine and Radiopharmaceutic Consumption (2017-2022)
-
10.6.6 United Arab Emirates Nuclear Medicine and Radiopharmaceutic Consumption (2017-2022)
-
10.7 Africa Consumption Analysis
-
10.7.1 Nigeria Nuclear Medicine and Radiopharmaceutic Consumption (2017-2022)
-
10.7.2 South Africa Nuclear Medicine and Radiopharmaceutic Consumption (2017-2022)
-
10.7.3 Egypt Nuclear Medicine and Radiopharmaceutic Consumption (2017-2022)
-
10.7.4 Algeria Nuclear Medicine and Radiopharmaceutic Consumption (2017-2022)
-
10.8 Oceania Consumption Analysis
-
10.8.1 Australia Nuclear Medicine and Radiopharmaceutic Consumption (2017-2022)
-
10.8.2 New Zealand Nuclear Medicine and Radiopharmaceutic Consumption (2017-2022)
11 Global Nuclear Medicine and Radiopharmaceutic Competitive Analysis
-
11.1 Dongcheng?
-
11.1.1 Dongcheng? Company Details
-
11.1.2 Dongcheng? Nuclear Medicine and Radiopharmaceutic Sales, Price, Value and Gross Profit (2017-2022)
-
11.1.3 Dongcheng? Nuclear Medicine and Radiopharmaceutic Main Business and Markets Served
-
11.1.4 Dongcheng? Nuclear Medicine and Radiopharmaceutic Product Portfolio
-
11.1.5 Recent Research and Development Strategies
-
11.2 China Isotope & Radiation?
-
11.2.1 China Isotope & Radiation? Company Details
-
11.2.2 China Isotope & Radiation? Nuclear Medicine and Radiopharmaceutic Sales, Price, Value and Gross Profit (2017-2022)
-
11.2.3 China Isotope & Radiation? Nuclear Medicine and Radiopharmaceutic Main Business and Markets Served
-
11.2.4 China Isotope & Radiation? Nuclear Medicine and Radiopharmaceutic Product Portfolio
-
11.2.5 Recent Research and Development Strategies
-
11.3 Nordion?
-
11.3.1 Nordion? Company Details
-
11.3.2 Nordion? Nuclear Medicine and Radiopharmaceutic Sales, Price, Value and Gross Profit (2017-2022)
-
11.3.3 Nordion? Nuclear Medicine and Radiopharmaceutic Main Business and Markets Served
-
11.3.4 Nordion? Nuclear Medicine and Radiopharmaceutic Product Portfolio
-
11.3.5 Recent Research and Development Strategies
-
11.4 SIEMENS?
-
11.4.1 SIEMENS? Company Details
-
11.4.2 SIEMENS? Nuclear Medicine and Radiopharmaceutic Sales, Price, Value and Gross Profit (2017-2022)
-
11.4.3 SIEMENS? Nuclear Medicine and Radiopharmaceutic Main Business and Markets Served
-
11.4.4 SIEMENS? Nuclear Medicine and Radiopharmaceutic Product Portfolio
-
11.4.5 Recent Research and Development Strategies
-
11.5 Bayer?
-
11.5.1 Bayer? Company Details
-
11.5.2 Bayer? Nuclear Medicine and Radiopharmaceutic Sales, Price, Value and Gross Profit (2017-2022)
-
11.5.3 Bayer? Nuclear Medicine and Radiopharmaceutic Main Business and Markets Served
-
11.5.4 Bayer? Nuclear Medicine and Radiopharmaceutic Product Portfolio
-
11.5.5 Recent Research and Development Strategies
-
11.6 IBA Group?
-
11.6.1 IBA Group? Company Details
-
11.6.2 IBA Group? Nuclear Medicine and Radiopharmaceutic Sales, Price, Value and Gross Profit (2017-2022)
-
11.6.3 IBA Group? Nuclear Medicine and Radiopharmaceutic Main Business and Markets Served
-
11.6.4 IBA Group? Nuclear Medicine and Radiopharmaceutic Product Portfolio
-
11.6.5 Recent Research and Development Strategies
-
11.7 GE Healthcare?
-
11.7.1 GE Healthcare? Company Details
-
11.7.2 GE Healthcare? Nuclear Medicine and Radiopharmaceutic Sales, Price, Value and Gross Profit (2017-2022)
-
11.7.3 GE Healthcare? Nuclear Medicine and Radiopharmaceutic Main Business and Markets Served
-
11.7.4 GE Healthcare? Nuclear Medicine and Radiopharmaceutic Product Portfolio
-
11.7.5 Recent Research and Development Strategies
-
11.8 Lantheus?
-
11.8.1 Lantheus? Company Details
-
11.8.2 Lantheus? Nuclear Medicine and Radiopharmaceutic Sales, Price, Value and Gross Profit (2017-2022)
-
11.8.3 Lantheus? Nuclear Medicine and Radiopharmaceutic Main Business and Markets Served
-
11.8.4 Lantheus? Nuclear Medicine and Radiopharmaceutic Product Portfolio
-
11.8.5 Recent Research and Development Strategies
-
11.9 Company?
-
11.9.1 Company? Company Details
-
11.9.2 Company? Nuclear Medicine and Radiopharmaceutic Sales, Price, Value and Gross Profit (2017-2022)
-
11.9.3 Company? Nuclear Medicine and Radiopharmaceutic Main Business and Markets Served
-
11.9.4 Company? Nuclear Medicine and Radiopharmaceutic Product Portfolio
-
11.9.5 Recent Research and Development Strategies
-
11.10 Eli Lilly?
-
11.10.1 Eli Lilly? Company Details
-
11.10.2 Eli Lilly? Nuclear Medicine and Radiopharmaceutic Sales, Price, Value and Gross Profit (2017-2022)
-
11.10.3 Eli Lilly? Nuclear Medicine and Radiopharmaceutic Main Business and Markets Served
-
11.10.4 Eli Lilly? Nuclear Medicine and Radiopharmaceutic Product Portfolio
-
11.10.5 Recent Research and Development Strategies
-
11.11 Bracco Imaging?
-
11.11.1 Bracco Imaging? Company Details
-
11.11.2 Bracco Imaging? Nuclear Medicine and Radiopharmaceutic Sales, Price, Value and Gross Profit (2017-2022)
-
11.11.3 Bracco Imaging? Nuclear Medicine and Radiopharmaceutic Main Business and Markets Served
-
11.11.4 Bracco Imaging? Nuclear Medicine and Radiopharmaceutic Product Portfolio
-
11.11.5 Recent Research and Development Strategies
-
11.12 Jubilant Pharma?
-
11.12.1 Jubilant Pharma? Company Details
-
11.12.2 Jubilant Pharma? Nuclear Medicine and Radiopharmaceutic Sales, Price, Value and Gross Profit (2017-2022)
-
11.12.3 Jubilant Pharma? Nuclear Medicine and Radiopharmaceutic Main Business and Markets Served
-
11.12.4 Jubilant Pharma? Nuclear Medicine and Radiopharmaceutic Product Portfolio
-
11.12.5 Recent Research and Development Strategies
-
11.13 Mallinckrodt?
-
11.13.1 Mallinckrodt? Company Details
-
11.13.2 Mallinckrodt? Nuclear Medicine and Radiopharmaceutic Sales, Price, Value and Gross Profit (2017-2022)
-
11.13.3 Mallinckrodt? Nuclear Medicine and Radiopharmaceutic Main Business and Markets Served
-
11.13.4 Mallinckrodt? Nuclear Medicine and Radiopharmaceutic Product Portfolio
-
11.13.5 Recent Research and Development Strategies
-
11.14 Navidea?
-
11.14.1 Navidea? Company Details
-
11.14.2 Navidea? Nuclear Medicine and Radiopharmaceutic Sales, Price, Value and Gross Profit (2017-2022)
-
11.14.3 Navidea? Nuclear Medicine and Radiopharmaceutic Main Business and Markets Served
-
11.14.4 Navidea? Nuclear Medicine and Radiopharmaceutic Product Portfolio
-
11.14.5 Recent Research and Development Strategies
-
11.15 Advanced Accelerator Applications?
-
11.15.1 Advanced Accelerator Applications? Company Details
-
11.15.2 Advanced Accelerator Applications? Nuclear Medicine and Radiopharmaceutic Sales, Price, Value and Gross Profit (2017-2022)
-
11.15.3 Advanced Accelerator Applications? Nuclear Medicine and Radiopharmaceutic Main Business and Markets Served
-
11.15.4 Advanced Accelerator Applications? Nuclear Medicine and Radiopharmaceutic Product Portfolio
-
11.15.5 Recent Research and Development Strategies
-
11.16 Triad Isotopes?
-
11.16.1 Triad Isotopes? Company Details
-
11.16.2 Triad Isotopes? Nuclear Medicine and Radiopharmaceutic Sales, Price, Value and Gross Profit (2017-2022)
-
11.16.3 Triad Isotopes? Nuclear Medicine and Radiopharmaceutic Main Business and Markets Served
-
11.16.4 Triad Isotopes? Nuclear Medicine and Radiopharmaceutic Product Portfolio
-
11.16.5 Recent Research and Development Strategies
12 Global Nuclear Medicine and Radiopharmaceutic Market Outlook by Types and Applications to 2028
-
12.1 Global Nuclear Medicine and Radiopharmaceutic Consumption Forecast and Growth Rate by Type (2022-2028)
-
12.1.1 Global Diagnostic Radioisotopes? Consumption Forecast and Growth Rate (2022-2028)
-
12.1.2 Global Therapeutic Radioisotopes Consumption Forecast and Growth Rate (2022-2028)
-
12.2 Global Nuclear Medicine and Radiopharmaceutic Consumption Forecast and Growth Rate by Application (2022-2028)
-
12.2.1 Global Oncology? Consumption Forecast and Growth Rate (2022-2028)
-
12.2.2 Global Cardiology? Consumption Forecast and Growth Rate (2022-2028)
-
12.2.3 Global Others? Consumption Forecast and Growth Rate (2022-2028)
13 Country-wise Nuclear Medicine and Radiopharmaceutic Market Analysis and Outlook to 2028
-
13.1 Global Nuclear Medicine and Radiopharmaceutic Consumption Forecast (2022-2028)
-
13.2 North America Consumption Analysis
-
13.2.1 United States Nuclear Medicine and Radiopharmaceutic Consumption Forecast (2022-2028)
-
13.2.2 Canada Nuclear Medicine and Radiopharmaceutic Consumption Forecast (2022-2028)
-
13.2.3 Mexico Nuclear Medicine and Radiopharmaceutic Consumption Forecast (2022-2028)
-
13.3 Europe Consumption Analysis
-
13.3.1 Germany Nuclear Medicine and Radiopharmaceutic Consumption Forecast (2022-2028)
-
13.3.2 UK Nuclear Medicine and Radiopharmaceutic Consumption Forecast (2022-2028)
-
13.3.3 Spain Nuclear Medicine and Radiopharmaceutic Consumption Forecast (2022-2028)
-
13.3.4 Belgium Nuclear Medicine and Radiopharmaceutic Consumption Forecast (2022-2028)
-
13.3.5 France Nuclear Medicine and Radiopharmaceutic Consumption Forecast (2022-2028)
-
13.3.6 Italy Nuclear Medicine and Radiopharmaceutic Consumption Forecast (2022-2028)
-
13.3.7 Denmark Nuclear Medicine and Radiopharmaceutic Consumption Forecast (2022-2028)
-
13.3.8 Finland Nuclear Medicine and Radiopharmaceutic Consumption Forecast (2022-2028)
-
13.3.9 Norway Nuclear Medicine and Radiopharmaceutic Consumption Forecast (2022-2028)
-
13.3.10 Sweden Nuclear Medicine and Radiopharmaceutic Consumption Forecast (2022-2028)
-
13.3.11 Poland Nuclear Medicine and Radiopharmaceutic Consumption Forecast (2022-2028)
-
13.3.12 Russia Nuclear Medicine and Radiopharmaceutic Consumption Forecast (2022-2028)
-
13.3.13 Turkey Nuclear Medicine and Radiopharmaceutic Consumption Forecast (2022-2028)
-
13.4 APAC Consumption Analysis
-
13.4.1 China Nuclear Medicine and Radiopharmaceutic Consumption Forecast (2022-2028)
-
13.4.2 Japan Nuclear Medicine and Radiopharmaceutic Consumption Forecast (2022-2028)
-
13.4.3 India Nuclear Medicine and Radiopharmaceutic Consumption Forecast (2022-2028)
-
13.4.4 South Korea Nuclear Medicine and Radiopharmaceutic Consumption Forecast (2022-2028)
-
13.4.5 Pakistan Nuclear Medicine and Radiopharmaceutic Consumption Forecast (2022-2028)
-
13.4.6 Bangladesh Nuclear Medicine and Radiopharmaceutic Consumption Forecast (2022-2028)
-
13.4.7 Indonesia Nuclear Medicine and Radiopharmaceutic Consumption Forecast (2022-2028)
-
13.4.8 Thailand Nuclear Medicine and Radiopharmaceutic Consumption Forecast (2022-2028)
-
13.4.9 Singapore Nuclear Medicine and Radiopharmaceutic Consumption Forecast (2022-2028)
-
13.4.10 Malaysia Nuclear Medicine and Radiopharmaceutic Consumption Forecast (2022-2028)
-
13.4.11 Philippines Nuclear Medicine and Radiopharmaceutic Consumption Forecast (2022-2028)
-
13.4.12 Vietnam Nuclear Medicine and Radiopharmaceutic Consumption Forecast (2022-2028)
-
13.5 South America Consumption Analysis
-
13.5.1 Brazil Nuclear Medicine and Radiopharmaceutic Consumption Forecast (2022-2028)
-
13.5.2 Colombia Nuclear Medicine and Radiopharmaceutic Consumption Forecast (2022-2028)
-
13.5.3 Chile Nuclear Medicine and Radiopharmaceutic Consumption Forecast (2022-2028)
-
13.5.4 Argentina Nuclear Medicine and Radiopharmaceutic Consumption Forecast (2022-2028)
-
13.5.5 Venezuela Nuclear Medicine and Radiopharmaceutic Consumption Forecast (2022-2028)
-
13.5.6 Peru Nuclear Medicine and Radiopharmaceutic Consumption Forecast (2022-2028)
-
13.5.7 Puerto Rico Nuclear Medicine and Radiopharmaceutic Consumption Forecast (2022-2028)
-
13.5.8 Ecuador Nuclear Medicine and Radiopharmaceutic Consumption Forecast (2022-2028)
-
13.6 GCC Consumption Analysis
-
13.6.1 Bahrain Nuclear Medicine and Radiopharmaceutic Consumption Forecast (2022-2028)
-
13.6.2 Kuwait Nuclear Medicine and Radiopharmaceutic Consumption Forecast (2022-2028)
-
13.6.3 Oman Nuclear Medicine and Radiopharmaceutic Consumption Forecast (2022-2028)
-
13.6.4 Qatar Nuclear Medicine and Radiopharmaceutic Consumption Forecast (2022-2028)
-
13.6.5 Saudi Arabia Nuclear Medicine and Radiopharmaceutic Consumption Forecast (2022-2028)
-
13.6.6 United Arab Emirates Nuclear Medicine and Radiopharmaceutic Consumption Forecast (2022-2028)
-
13.7 Africa Consumption Analysis
-
13.7.1 Nigeria Nuclear Medicine and Radiopharmaceutic Consumption Forecast (2022-2028)
-
13.7.2 South Africa Nuclear Medicine and Radiopharmaceutic Consumption Forecast (2022-2028)
-
13.7.3 Egypt Nuclear Medicine and Radiopharmaceutic Consumption Forecast (2022-2028)
-
13.7.4 Algeria Nuclear Medicine and Radiopharmaceutic Consumption Forecast (2022-2028)
-
13.8 Oceania Consumption Analysis
-
13.8.1 Australia Nuclear Medicine and Radiopharmaceutic Consumption Forecast (2022-2028)
-
13.8.2 New Zealand Nuclear Medicine and Radiopharmaceutic Consumption Forecast (2022-2028)
14 Conclusions
The List of Tables and Figures
-
Table Definition of Nuclear Medicine and Radiopharmaceutic
-
Figure of Nuclear Medicine and Radiopharmaceutic Picture
-
Table Global Nuclear Medicine and Radiopharmaceutic Import by Region (Top 10 Countries) (2017-2028)
-
Table Global Nuclear Medicine and Radiopharmaceutic Export by Region (Top 10 Countries) (2017-2028)
-
Figure Global Diagnostic Radioisotopes? Consumption and Growth Rate (2017-2022)
-
Figure Global Therapeutic Radioisotopes Consumption and Growth Rate (2017-2022)
-
Figure Global Oncology? Consumption and Growth Rate (2017-2022)
-
Figure Global Cardiology? Consumption and Growth Rate (2017-2022)
-
Figure Global Others? Consumption and Growth Rate (2017-2022)
-
Figure Global Nuclear Medicine and Radiopharmaceutic Consumption by Country (2017-2022)
-
Table North America Nuclear Medicine and Radiopharmaceutic Consumption by Country (2017-2022)
-
Figure United States Nuclear Medicine and Radiopharmaceutic Consumption and Growth Rate (2017-2022)
-
Figure Canada Nuclear Medicine and Radiopharmaceutic Consumption and Growth Rate (2017-2022)
-
Figure Mexico Nuclear Medicine and Radiopharmaceutic Consumption and Growth Rate (2017-2022)
-
Table Europe Nuclear Medicine and Radiopharmaceutic Consumption by Country (2017-2022)
-
Figure Germany Nuclear Medicine and Radiopharmaceutic Consumption and Growth Rate (2017-2022)
-
Figure UK Nuclear Medicine and Radiopharmaceutic Consumption and Growth Rate (2017-2022)
-
Figure Spain Nuclear Medicine and Radiopharmaceutic Consumption and Growth Rate (2017-2022)
-
Figure Belgium Nuclear Medicine and Radiopharmaceutic Consumption and Growth Rate (2017-2022)
-
Figure France Nuclear Medicine and Radiopharmaceutic Consumption and Growth Rate (2017-2022)
-
Figure Italy Nuclear Medicine and Radiopharmaceutic Consumption and Growth Rate (2017-2022)
-
Figure Denmark Nuclear Medicine and Radiopharmaceutic Consumption and Growth Rate (2017-2022)
-
Figure Finland Nuclear Medicine and Radiopharmaceutic Consumption and Growth Rate (2017-2022)
-
Figure Norway Nuclear Medicine and Radiopharmaceutic Consumption and Growth Rate (2017-2022)
-
Figure Sweden Nuclear Medicine and Radiopharmaceutic Consumption and Growth Rate (2017-2022)
-
Figure Poland Nuclear Medicine and Radiopharmaceutic Consumption and Growth Rate (2017-2022)
-
Figure Russia Nuclear Medicine and Radiopharmaceutic Consumption and Growth Rate (2017-2022)
-
Figure Turkey Nuclear Medicine and Radiopharmaceutic Consumption and Growth Rate (2017-2022)
-
Table APAC Nuclear Medicine and Radiopharmaceutic Consumption by Country (2017-2022)
-
Figure China Nuclear Medicine and Radiopharmaceutic Consumption and Growth Rate (2017-2022)
-
Figure Japan Nuclear Medicine and Radiopharmaceutic Consumption and Growth Rate (2017-2022)
-
Figure India Nuclear Medicine and Radiopharmaceutic Consumption and Growth Rate (2017-2022)
-
Figure South Korea Nuclear Medicine and Radiopharmaceutic Consumption and Growth Rate (2017-2022)
-
Figure Pakistan Nuclear Medicine and Radiopharmaceutic Consumption and Growth Rate (2017-2022)
-
Figure Bangladesh Nuclear Medicine and Radiopharmaceutic Consumption and Growth Rate (2017-2022)
-
Figure Indonesia Nuclear Medicine and Radiopharmaceutic Consumption and Growth Rate (2017-2022)
-
Figure Thailand Nuclear Medicine and Radiopharmaceutic Consumption and Growth Rate (2017-2022)
-
Figure Singapore Nuclear Medicine and Radiopharmaceutic Consumption and Growth Rate (2017-2022)
-
Figure Malaysia Nuclear Medicine and Radiopharmaceutic Consumption and Growth Rate (2017-2022)
-
Figure Philippines Nuclear Medicine and Radiopharmaceutic Consumption and Growth Rate (2017-2022)
-
Figure Vietnam Nuclear Medicine and Radiopharmaceutic Consumption and Growth Rate (2017-2022)
-
Table South America Nuclear Medicine and Radiopharmaceutic Consumption by Country (2017-2022)
-
Figure Brazil Nuclear Medicine and Radiopharmaceutic Consumption and Growth Rate (2017-2022)
-
Figure Colombia Nuclear Medicine and Radiopharmaceutic Consumption and Growth Rate (2017-2022)
-
Figure Chile Nuclear Medicine and Radiopharmaceutic Consumption and Growth Rate (2017-2022)
-
Figure Argentina Nuclear Medicine and Radiopharmaceutic Consumption and Growth Rate (2017-2022)
-
Figure Venezuela Nuclear Medicine and Radiopharmaceutic Consumption and Growth Rate (2017-2022)
-
Figure Peru Nuclear Medicine and Radiopharmaceutic Consumption and Growth Rate (2017-2022)
-
Figure Puerto Rico Nuclear Medicine and Radiopharmaceutic Consumption and Growth Rate (2017-2022)
-
Figure Ecuador Nuclear Medicine and Radiopharmaceutic Consumption and Growth Rate (2017-2022)
-
Table GCC Nuclear Medicine and Radiopharmaceutic Consumption by Country (2017-2022)
-
Figure Bahrain Nuclear Medicine and Radiopharmaceutic Consumption and Growth Rate (2017-2022)
-
Figure Kuwait Nuclear Medicine and Radiopharmaceutic Consumption and Growth Rate (2017-2022)
-
Figure Oman Nuclear Medicine and Radiopharmaceutic Consumption and Growth Rate (2017-2022)
-
Figure Qatar Nuclear Medicine and Radiopharmaceutic Consumption and Growth Rate (2017-2022)
-
Figure Saudi Arabia Nuclear Medicine and Radiopharmaceutic Consumption and Growth Rate (2017-2022)
-
Figure United Arab Emirates Nuclear Medicine and Radiopharmaceutic Consumption and Growth Rate (2017-2022)
-
Table Africa Nuclear Medicine and Radiopharmaceutic Consumption by Country (2017-2022)
-
Figure Nigeria Nuclear Medicine and Radiopharmaceutic Consumption and Growth Rate (2017-2022)
-
Figure South Africa Nuclear Medicine and Radiopharmaceutic Consumption and Growth Rate (2017-2022)
-
Figure Egypt Nuclear Medicine and Radiopharmaceutic Consumption and Growth Rate (2017-2022)
-
Figure Algeria Nuclear Medicine and Radiopharmaceutic Consumption and Growth Rate (2017-2022)
-
Table Oceania Nuclear Medicine and Radiopharmaceutic Consumption by Country (2017-2022)
-
Figure Australia Nuclear Medicine and Radiopharmaceutic Consumption and Growth Rate (2017-2022)
-
Figure New Zealand Nuclear Medicine and Radiopharmaceutic Consumption and Growth Rate (2017-2022)
-
Table Dongcheng? Company Details
-
Table Dongcheng? Nuclear Medicine and Radiopharmaceutic Sales, Price, Value and Gross Profit (2017-2022)
-
Table Dongcheng? Nuclear Medicine and Radiopharmaceutic Main Business and Markets Served
-
Table Dongcheng? Nuclear Medicine and Radiopharmaceutic Product Portfolio
-
Table China Isotope & Radiation? Company Details
-
Table China Isotope & Radiation? Nuclear Medicine and Radiopharmaceutic Sales, Price, Value and Gross Profit (2017-2022)
-
Table China Isotope & Radiation? Nuclear Medicine and Radiopharmaceutic Main Business and Markets Served
-
Table China Isotope & Radiation? Nuclear Medicine and Radiopharmaceutic Product Portfolio
-
Table Nordion? Company Details
-
Table Nordion? Nuclear Medicine and Radiopharmaceutic Sales, Price, Value and Gross Profit (2017-2022)
-
Table Nordion? Nuclear Medicine and Radiopharmaceutic Main Business and Markets Served
-
Table Nordion? Nuclear Medicine and Radiopharmaceutic Product Portfolio
-
Table SIEMENS? Company Details
-
Table SIEMENS? Nuclear Medicine and Radiopharmaceutic Sales, Price, Value and Gross Profit (2017-2022)
-
Table SIEMENS? Nuclear Medicine and Radiopharmaceutic Main Business and Markets Served
-
Table SIEMENS? Nuclear Medicine and Radiopharmaceutic Product Portfolio
-
Table Bayer? Company Details
-
Table Bayer? Nuclear Medicine and Radiopharmaceutic Sales, Price, Value and Gross Profit (2017-2022)
-
Table Bayer? Nuclear Medicine and Radiopharmaceutic Main Business and Markets Served
-
Table Bayer? Nuclear Medicine and Radiopharmaceutic Product Portfolio
-
Table IBA Group? Company Details
-
Table IBA Group? Nuclear Medicine and Radiopharmaceutic Sales, Price, Value and Gross Profit (2017-2022)
-
Table IBA Group? Nuclear Medicine and Radiopharmaceutic Main Business and Markets Served
-
Table IBA Group? Nuclear Medicine and Radiopharmaceutic Product Portfolio
-
Table GE Healthcare? Company Details
-
Table GE Healthcare? Nuclear Medicine and Radiopharmaceutic Sales, Price, Value and Gross Profit (2017-2022)
-
Table GE Healthcare? Nuclear Medicine and Radiopharmaceutic Main Business and Markets Served
-
Table GE Healthcare? Nuclear Medicine and Radiopharmaceutic Product Portfolio
-
Table Lantheus? Company Details
-
Table Lantheus? Nuclear Medicine and Radiopharmaceutic Sales, Price, Value and Gross Profit (2017-2022)
-
Table Lantheus? Nuclear Medicine and Radiopharmaceutic Main Business and Markets Served
-
Table Lantheus? Nuclear Medicine and Radiopharmaceutic Product Portfolio
-
Table Company? Company Details
-
Table Company? Nuclear Medicine and Radiopharmaceutic Sales, Price, Value and Gross Profit (2017-2022)
-
Table Company? Nuclear Medicine and Radiopharmaceutic Main Business and Markets Served
-
Table Company? Nuclear Medicine and Radiopharmaceutic Product Portfolio
-
Table Eli Lilly? Company Details
-
Table Eli Lilly? Nuclear Medicine and Radiopharmaceutic Sales, Price, Value and Gross Profit (2017-2022)
-
Table Eli Lilly? Nuclear Medicine and Radiopharmaceutic Main Business and Markets Served
-
Table Eli Lilly? Nuclear Medicine and Radiopharmaceutic Product Portfolio
-
Table Bracco Imaging? Company Details
-
Table Bracco Imaging? Nuclear Medicine and Radiopharmaceutic Sales, Price, Value and Gross Profit (2017-2022)
-
Table Bracco Imaging? Nuclear Medicine and Radiopharmaceutic Main Business and Markets Served
-
Table Bracco Imaging? Nuclear Medicine and Radiopharmaceutic Product Portfolio
-
Table Jubilant Pharma? Company Details
-
Table Jubilant Pharma? Nuclear Medicine and Radiopharmaceutic Sales, Price, Value and Gross Profit (2017-2022)
-
Table Jubilant Pharma? Nuclear Medicine and Radiopharmaceutic Main Business and Markets Served
-
Table Jubilant Pharma? Nuclear Medicine and Radiopharmaceutic Product Portfolio
-
Table Mallinckrodt? Company Details
-
Table Mallinckrodt? Nuclear Medicine and Radiopharmaceutic Sales, Price, Value and Gross Profit (2017-2022)
-
Table Mallinckrodt? Nuclear Medicine and Radiopharmaceutic Main Business and Markets Served
-
Table Mallinckrodt? Nuclear Medicine and Radiopharmaceutic Product Portfolio
-
Table Navidea? Company Details
-
Table Navidea? Nuclear Medicine and Radiopharmaceutic Sales, Price, Value and Gross Profit (2017-2022)
-
Table Navidea? Nuclear Medicine and Radiopharmaceutic Main Business and Markets Served
-
Table Navidea? Nuclear Medicine and Radiopharmaceutic Product Portfolio
-
Table Advanced Accelerator Applications? Company Details
-
Table Advanced Accelerator Applications? Nuclear Medicine and Radiopharmaceutic Sales, Price, Value and Gross Profit (2017-2022)
-
Table Advanced Accelerator Applications? Nuclear Medicine and Radiopharmaceutic Main Business and Markets Served
-
Table Advanced Accelerator Applications? Nuclear Medicine and Radiopharmaceutic Product Portfolio
-
Table Triad Isotopes? Company Details
-
Table Triad Isotopes? Nuclear Medicine and Radiopharmaceutic Sales, Price, Value and Gross Profit (2017-2022)
-
Table Triad Isotopes? Nuclear Medicine and Radiopharmaceutic Main Business and Markets Served
-
Table Triad Isotopes? Nuclear Medicine and Radiopharmaceutic Product Portfolio
-
Figure Global Diagnostic Radioisotopes? Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Therapeutic Radioisotopes Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Oncology? Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Cardiology? Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Others? Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Nuclear Medicine and Radiopharmaceutic Consumption Forecast by Country (2022-2028)
-
Table North America Nuclear Medicine and Radiopharmaceutic Consumption Forecast by Country (2022-2028)
-
Figure United States Nuclear Medicine and Radiopharmaceutic Consumption Forecast and Growth Rate (2022-2028)
-
Figure Canada Nuclear Medicine and Radiopharmaceutic Consumption Forecast and Growth Rate (2022-2028)
-
Figure Mexico Nuclear Medicine and Radiopharmaceutic Consumption Forecast and Growth Rate (2022-2028)
-
Table Europe Nuclear Medicine and Radiopharmaceutic Consumption Forecast by Country (2022-2028)
-
Figure Germany Nuclear Medicine and Radiopharmaceutic Consumption Forecast and Growth Rate (2022-2028)
-
Figure UK Nuclear Medicine and Radiopharmaceutic Consumption Forecast and Growth Rate (2022-2028)
-
Figure Spain Nuclear Medicine and Radiopharmaceutic Consumption Forecast and Growth Rate (2022-2028)
-
Figure Belgium Nuclear Medicine and Radiopharmaceutic Consumption Forecast and Growth Rate (2022-2028)
-
Figure France Nuclear Medicine and Radiopharmaceutic Consumption Forecast and Growth Rate (2022-2028)
-
Figure Italy Nuclear Medicine and Radiopharmaceutic Consumption Forecast and Growth Rate (2022-2028)
-
Figure Denmark Nuclear Medicine and Radiopharmaceutic Consumption Forecast and Growth Rate (2022-2028)
-
Figure Finland Nuclear Medicine and Radiopharmaceutic Consumption Forecast and Growth Rate (2022-2028)
-
Figure Norway Nuclear Medicine and Radiopharmaceutic Consumption Forecast and Growth Rate (2022-2028)
-
Figure Sweden Nuclear Medicine and Radiopharmaceutic Consumption Forecast and Growth Rate (2022-2028)
-
Figure Poland Nuclear Medicine and Radiopharmaceutic Consumption Forecast and Growth Rate (2022-2028)
-
Figure Russia Nuclear Medicine and Radiopharmaceutic Consumption Forecast and Growth Rate (2022-2028)
-
Figure Turkey Nuclear Medicine and Radiopharmaceutic Consumption Forecast and Growth Rate (2022-2028)
-
Table APAC Nuclear Medicine and Radiopharmaceutic Consumption Forecast by Country (2022-2028)
-
Figure China Nuclear Medicine and Radiopharmaceutic Consumption Forecast and Growth Rate (2022-2028)
-
Figure Japan Nuclear Medicine and Radiopharmaceutic Consumption Forecast and Growth Rate (2022-2028)
-
Figure India Nuclear Medicine and Radiopharmaceutic Consumption Forecast and Growth Rate (2022-2028)
-
Figure South Korea Nuclear Medicine and Radiopharmaceutic Consumption Forecast and Growth Rate (2022-2028)
-
Figure Pakistan Nuclear Medicine and Radiopharmaceutic Consumption Forecast and Growth Rate (2022-2028)
-
Figure Bangladesh Nuclear Medicine and Radiopharmaceutic Consumption Forecast and Growth Rate (2022-2028)
-
Figure Indonesia Nuclear Medicine and Radiopharmaceutic Consumption Forecast and Growth Rate (2022-2028)
-
Figure Thailand Nuclear Medicine and Radiopharmaceutic Consumption Forecast and Growth Rate (2022-2028)
-
Figure Singapore Nuclear Medicine and Radiopharmaceutic Consumption Forecast and Growth Rate (2022-2028)
-
Figure Malaysia Nuclear Medicine and Radiopharmaceutic Consumption Forecast and Growth Rate (2022-2028)
-
Figure Philippines Nuclear Medicine and Radiopharmaceutic Consumption Forecast and Growth Rate (2022-2028)
-
Figure Vietnam Nuclear Medicine and Radiopharmaceutic Consumption Forecast and Growth Rate (2022-2028)
-
Table South America Nuclear Medicine and Radiopharmaceutic Consumption Forecast by Country (2022-2028)
-
Figure Brazil Nuclear Medicine and Radiopharmaceutic Consumption Forecast and Growth Rate (2022-2028)
-
Figure Colombia Nuclear Medicine and Radiopharmaceutic Consumption Forecast and Growth Rate (2022-2028)
-
Figure Chile Nuclear Medicine and Radiopharmaceutic Consumption Forecast and Growth Rate (2022-2028)
-
Figure Argentina Nuclear Medicine and Radiopharmaceutic Consumption Forecast and Growth Rate (2022-2028)
-
Figure Venezuela Nuclear Medicine and Radiopharmaceutic Consumption Forecast and Growth Rate (2022-2028)
-
Figure Peru Nuclear Medicine and Radiopharmaceutic Consumption Forecast and Growth Rate (2022-2028)
-
Figure Puerto Rico Nuclear Medicine and Radiopharmaceutic Consumption Forecast and Growth Rate (2022-2028)
-
Figure Ecuador Nuclear Medicine and Radiopharmaceutic Consumption Forecast and Growth Rate (2022-2028)
-
Table GCC Nuclear Medicine and Radiopharmaceutic Consumption Forecast by Country (2022-2028)
-
Figure Bahrain Nuclear Medicine and Radiopharmaceutic Consumption Forecast and Growth Rate (2022-2028)
-
Figure Kuwait Nuclear Medicine and Radiopharmaceutic Consumption Forecast and Growth Rate (2022-2028)
-
Figure Oman Nuclear Medicine and Radiopharmaceutic Consumption Forecast and Growth Rate (2022-2028)
-
Figure Qatar Nuclear Medicine and Radiopharmaceutic Consumption Forecast and Growth Rate (2022-2028)
-
Figure Saudi Arabia Nuclear Medicine and Radiopharmaceutic Consumption Forecast and Growth Rate (2022-2028)
-
Figure United Arab Emirates Nuclear Medicine and Radiopharmaceutic Consumption Forecast and Growth Rate (2022-2028)
-
Table Africa Nuclear Medicine and Radiopharmaceutic Consumption Forecast by Country (2022-2028)
-
Figure Nigeria Nuclear Medicine and Radiopharmaceutic Consumption Forecast and Growth Rate (2022-2028)
-
Figure South Africa Nuclear Medicine and Radiopharmaceutic Consumption Forecast and Growth Rate (2022-2028)
-
Figure Egypt Nuclear Medicine and Radiopharmaceutic Consumption Forecast and Growth Rate (2022-2028)
-
Figure Algeria Nuclear Medicine and Radiopharmaceutic Consumption Forecast and Growth Rate (2022-2028)
-
Table Oceania Nuclear Medicine and Radiopharmaceutic Consumption Forecast by Country (2022-2028)
-
Figure Australia Nuclear Medicine and Radiopharmaceutic Consumption Forecast and Growth Rate (2022-2028)
-
Figure New Zealand Nuclear Medicine and Radiopharmaceutic Consumption Forecast and Growth Rate (2022-2028)
-
